多发性骨髓瘤的治疗:ASCO与CCO联合临床实践指南
ASCO与加拿大安大略癌症治疗中心(CCO)召集专家组,检索2005年至2018年发表的系统评价、荟萃分析、随机对照试验及部分II期研究,共纳入124项相关研究,针对适合移植、不适合移植及复发或难治性多发性骨髓瘤患者制定循证推荐。
要点
- 指南覆盖适合移植、不适合移植及复发或难治性多发性骨髓瘤三类患者。
- 证据基础包括124项相关研究,含系统评价、荟萃分析、随机对照试验及部分II期研究。
- 推荐基于现有证据及专家组非正式共识制定。
核心结论
- ASCO与CCO联合发布多发性骨髓瘤治疗循证推荐,覆盖适合移植、不适合移植及复发或难治性患者。
研究设计与样本
- ASCO与加拿大安大略癌症治疗中心(CCO)召集肿瘤内科、外科、放射肿瘤及患者倡导专家组成专家组。
- 检索2005年至2018年发表的系统评价、荟萃分析、随机对照试验及部分II期研究。
- 共识别124项相关研究作为证据基础。
- 专家组基于现有证据及非正式共识制定循证指南推荐。
主要发现
- 文献检索共识别124项相关研究,用于构建本指南的证据基础。
- 关注的结局包括生存、无进展生存、缓解率和生活质量。
关键数值与推荐
- 针对适合移植的多发性骨髓瘤患者制定循证推荐。
- 针对不适合移植的多发性骨髓瘤患者制定循证推荐。
- 针对复发或难治性多发性骨髓瘤患者制定循证推荐。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations on the treatment of multiple myeloma to practicing physicians and others. METHODS: ASCO and Cancer Care Ontario convened an Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and some phase II studies published from 2005 through 2018. Outcomes of interest included survival, progression-free survival, response rate, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 124 relevant studies to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations were developed for patients with multiple myeloma who are transplantation eligible and those who are ineligible and for patients with relapsed or refractory disease.
引用
- Mikhael J, Ismaila N, Cheung MC, et al. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. J Clin Oncol. 2019. PMID: 30932732. doi:10.1200/JCO.18.02096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。